Celldex to Present at Upcoming Investor Conferences
Celldex (NASDAQ:CLDX) said management will participate in three investor conference fireside chats in November and December 2025.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Celldex (NASDAQ:CLDX) said management will participate in three investor conference fireside chats in November and December 2025.
Scheduled events: Guggenheim Healthcare Innovation on Nov 11, 2025 at 10:00 AM ET; Cowen Immunology & Inflammation Summit on Nov 13, 2025 at 9:30 AM ET; and Evercore Healthcare Conference on Dec 2, 2025 at 3:00 PM ET. Live webcasts will be available on the company's Investors > Events & Presentations page, with replays accessible for 90 days after each event.
Details
News Market Reaction – CLDX
On Nov 7, the day this news came out, CLDX closed 1.55% below the previous close.
Data tracked by StockTitan Argus for the Nov 7 session.
AI-generated analysis. How Rhea-AI works. Not financial advice.
HAMPTON, N.J., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today that management will participate in fireside chats at the following upcoming investor conferences:
- Guggenheim 2nd Annual Healthcare Innovation Conference on Tuesday, November 11 at 10:00 am ET
- TD Cowen Immunology & Inflammation Summit on Thursday, November 13 at 9:30 am ET
- 8th Annual Evercore Healthcare Conference on Tuesday, December 2 at 3:00 pm ET
Live webcasts of the presentations will be available on the "Events & Presentations" page of the "Investors" section of the Celldex website. Replays will be available for 90 days following the event.
About Celldex
Celldex is pioneering new horizons in immunology to deliver life-changing therapies. We are relentless in our pursuit of novel antibody-based treatments that engage the human immune system and directly affect critical pathways to improve the lives of patients with allergic, inflammatory and autoimmune disorders.
Visit www.celldex.com.
Company Contact
Sarah Cavanaugh
Senior Vice President, Corporate Affairs & Administration
(508) 864-8337
scavanaugh@celldex.com
Patrick Till
Meru Advisors
(484) 788-8560
ptill@meruadvisors.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.